The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults
Open accessAbstract
BACKGROUND: Respiratory syncytial virus (RSV) can cause substantial morbidity and mortality among older adults. An mRNA-based RSV vaccine, mRNA-1345, encoding the stabilized RSV prefusion F glycoprotein, is under clinical investigation. METHODS: In this ongoing, randomized, double-blind, placebo-controlled, phase 2-3 trial, we randomly assigned, in a 1:1 ratio, adults 60 years of age or older to receive one dose of mRNA-1345 (50 μg) or placebo. The two primary efficacy end points were the prevention of RSV-associated lower respiratory tract disease with at least two signs or symptoms and with at least three signs or symptoms. A key secondary efficacy end point was the prevention of RSV-associated acute respiratory disease. Safety was also assessed. RESULTS: Overall, 35,541 participants were assigned to receive the mRNA-1345 vaccine (17,793 participants) or placebo (17,748). The median follow-up was 112 days (range, 1 to 379). The primary analyses were conducted when at least 50% of the anticipated cases of RSV-associated lower respiratory tract disease had occurred. Vaccine efficacy was 83.7% (95.88% confidence interval [CI], 66.0 to 92.2) against RSV-associated lower respiratory tract disease with at least two signs or symptoms and 82.4% (96.36% CI, 34.8 to 95.3) against the disease with at least three signs or symptoms. Vaccine efficacy was 68.4% (95% CI, 50.9 to 79.7) against RSV-associated acute respiratory disease. Protection was observed against both RSV subtypes (A and B) and was generally consistent across subgroups defined according to age and coexisting conditions. Participants in the mRNA-1345 group had a higher incidence than those in the placebo group of solicited local adverse reactions (58.7% vs. 16.2%) and of systemic adverse reactions (47.7% vs. 32.9%); most reactions were mild to moderate in severity and were transient. Serious adverse events occurred in 2.8% of the participants in each trial group. CONCLUSIONS: A single dose of the mRNA-1345 vaccine resulted in no evident safety concerns and led to a lower incidence of RSV-associated lower respiratory tract disease and of RSV-associated acute respiratory disease than placebo among adults 60 years of age or older. (Funded by Moderna; ConquerRSV ClinicalTrials.gov number, NCT05127434.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality Associated With Influenza and Respiratory Syncytial Virus in the United States
Thompson, W. W., Shay, D. K., Weintraub, E., Brammer, L., Cox, N., Anderson, L. J., & Fukuda, K. (2003) · JAMA · doi:10.1001/jama.289.2.179 · Cited by 3,673
Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults
Falsey, A. R., Hennessey, P. A., Formica, M. A., Cox, C., & Walsh, E. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043951 · Cited by 2,226
Self-citationValidity and reliability of the Edmonton Frail Scale
Rolfson, D. B., Majumdar, S. R., Tsuyuki, R. T., Tahir, A., & Rockwood, K. (2006) · Age and Ageing · doi:10.1093/ageing/afl041 · Cited by 1,643
Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus
McLellan, J. S., Chen, M., Joyce, M. G., Sastry, M., Stewart-Jones, G. B. E., Yang, Y., Zhang, B., Chen, L., Srivatsan, S., Zheng, A., et al. (2013) · Science · doi:10.1126/science.1243283 · Cited by 1,126
Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody
McLellan, J. S., Chen, M., Leung, S., Graepel, K. W., Du, X., Yang, Y., Zhou, T., Baxa, U., Yasuda, E., Beaumont, T., et al. (2013) · Science · doi:10.1126/science.1234914 · Cited by 883
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults
Papi, A., Ison, M. G., Langley, J. M., Lee, D.-G., Leroux-Roels, I., Martinon-Torres, F., Schwarz, T. F., van Zyl-Smit, R. N., Campora, L., Dezutter, N., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2209604 · Cited by 774
Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults
Walsh, E. E., Pérez Marc, G., Zareba, A. M., Falsey, A. R., Jiang, Q., Patton, M., Polack, F. P., Llapur, C., Doreski, P. A., Ilangovan, K., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2213836 · Cited by 668
Self-citationA Bivalent Omicron-Containing Booster Vaccine against Covid-19
Chalkias, S., Harper, C., Vrbicky, K., Walsh, S. R., Essink, B., Brosz, A., McGhee, N., Tomassini, J. E., Chen, X., Chang, Y., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2208343 · Cited by 627
Self-citationRespiratory syncytial virus infection
Simoes, E. A. (1999) · The Lancet · doi:10.1016/s0140-6736(99)80040-3 · Cited by 603
Respiratory Syncytial Virus Infection in Adults
Falsey, A. R., & Walsh, E. E. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.3.371 · Cited by 438
Self-citation
Cited by
Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults
Leroux-Roels, I., Huang, G., Ferguson, M., Kohli, A., Clark, R., Bickel, M., Soens, M., Du, E., Pucci, A., Hicks, B., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2516491 · Cited by 37
Self-citationKnowledge and Attitudes Regarding Respiratory Syncytial Virus (RSV) Prevention: A Systematic Review
Gavaruzzi, T., Ceccarelli, A., Nanni, C., Vignali, C., Colonnello, V., Caserotti, M., Riccò, M., & Gori, D. (2025) · Vaccines · doi:10.3390/vaccines13020159 · Cited by 29
Metadata
- Authors
- Wilson, E., Goswami, J., Baqui, A. H., Doreski, P. A., Perez-Marc, G., Zaman, K., Monroy, J., Duncan, C. J. A., Ujiie, M., Rämet, M., Pérez-Breva, L., Falsey, A. R., Walsh, E. E., Dhar, R., Wilson, L., Du, J., Ghaswalla, P., Kapoor, A., Lan, L., Mehta, S., Mithani, R., Panozzo, C. A., Simorellis, A. K., Kuter, B. J., Schödel, F., Huang, W., Reuter, C., Slobod, K., Stoszek, S. K., Shaw, C. A., Miller, J. M., Das, R., & Chen, G. L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-14
- Volume
- 389
- Issue
- 24
- Pages
- 2233-2244
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4389660759
- Cited by
- 500
- References
- 28
- FWCI
- 83.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults. https://app.cochat.ai/papers/10.1056/nejmoa2307079
- The paper
- Wilson, E., Goswami, J., Baqui, A. H., Doreski, P. A., Perez-Marc, G., Zaman, K., Monroy, J., Duncan, C. J. A., Ujiie, M., Rämet, M., Pérez-Breva, L., Falsey, A. R., Walsh, E. E., Dhar, R., Wilson, L., Du, J., Ghaswalla, P., Kapoor, A., Lan, L., . . . Chen, G. L. (2023). Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2307079
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.